ArticleFrontiers in immunology2013
Variation between Populations in the Innate Immune Response to Vaccine Adjuvants.
Article in Frontiers in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Over-dispersion in malaria-schistosoma co-infection: insights from a meta-analytical approach and systematic review.Infectious diseases of poverty · 2026Pooled it
- Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study.Human vaccines & immunotherapeutics · 2019Trial
- Rational design of next-generation vaccine adjuvants: From molecular mechanisms to hybrid delivery platforms.Human vaccines & immunotherapeutics · 2026Review
- Unleashing the power of the BCG vaccine in modulating viral immunity through heterologous protection: A scoping review.Human vaccines & immunotherapeutics · 2025Article
- Multi-dimensional analysis of B cells reveals the expansion of memory and regulatory B-cell clusters in humans living in rural tropical areas.Clinical and experimental immunology · 2025Article
- Vaccine adjuvants: mechanisms and platforms.Signal transduction and targeted therapy · 2023Review
- Effectiveness of Naturally Acquired and Vaccine-Induced Immune Responses to SARS-CoV-2 Mu Variant.Emerging infectious diseases · 2022Article
- Bacille Calmette-Guérin vaccine reprograms human neonatal lipid metabolism in vivo and in vitro.Cell reports · 2022Article
- Designing a Recombinant Vaccine againstVaccines · 2022Article
- Subsequent AS01-adjuvanted vaccinations induce similar transcriptional responses in populations with different disease statuses.PloS one · 2022Article
- Mutations Associated with SARS-CoV-2 Variants of Concern, Benin, Early 2021.Emerging infectious diseases · 2021Article
- Population matched (pm) germline allelic variants of immunoglobulin (IG) loci: Relevance in infectious diseases and vaccination studies in human populations.Genes and immunity · 2021Article
- Self-amplifying RNA vaccines for infectious diseases.Gene therapy · 2021Review
- Biogeography of the Relationship between the Child Gut Microbiome and Innate Immune System.mBio · 2021Article
- Type I IFN ineffectively activates neonatal dendritic cells limiting respiratory antiviral T-cell responses.Mucosal immunology · 2020Article
- Personalized Human Papillomavirus Vaccination for Persistence of Immunity for Cervical Cancer Prevention: A Critical Review With Experts' Opinions.Frontiers in oncology · 2020Review
- Differential IL-18 Dependence of Canonical and Adaptive NK Cells for Antibody Dependent Responses toFrontiers in immunology · 2020Article
- A biocultural approach to psychiatric illnesses.Psychopharmacology · 2019Review
- The Importance of Iron Status for Young Children in Low- and Middle-Income Countries: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Increased T Cell Differentiation and Cytolytic Function in Bangladeshi Compared to American Children.Frontiers in immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The success of the World Health Organization recommended "Expanded Program of Immunization" (EPI) and similar regional or national programs has been astounding. However, infectious threats currently not covered by these programs continue to infect millions of infants around the world. Furthermore, many infants do not receive existing vaccines either on time or for the required number of doses to provide optimal protection. Nor do all infants around the world develop the same protective immune response to the same vaccine. As a result approximately three million infants die every year from vaccine preventable infections. To tackle these issues, new vaccines need to be developed as well as existing ones made easier to administer. This requires identification of age-optimized vaccine schedules and formulations. In order to be most effective this approach will need to take population-based differences in response to vaccines and adjuvants into account. This review summarizes what is currently known about differences between populations around the world in the innate immune response to existing as well as new and promising vaccine adjuvants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.